AzTrials
AzTrials

Second Hand Tobacco SmokeNCT02928536

The TackSHS Survey: a Pan-European Study on SHS

An observational study of Second Hand Tobacco Smoke, run by Mario Negri Institute for Pharmacological Research at 1 site in Italy.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Within the TackSHS project (H2020 project grant agreement No 681040), we will conduct a European cross-sectional study, aiming at i) estimating prevalence and investigating determinants of smoking, e-cigarette use and exposure to SHS and to e-cigarette aerosol; ii) analyzing the attitudes, perceptions and behaviours… Read more about this study

Who is it for?
Ages 15 years and olderHealthy volunteers can take part
Conditions the study is for
Second Hand Tobacco Smoke
How many people
11,902 participants
Where
1 siteItaly
Study dates
Dec 2016to Oct 2018
Phase
Observational
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 15 years and older
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: In each of the 12 selected European countries, approximately 1000 individuals, representative of the general population aged 15 years and over in terms of age, sex, geographic area, and socio-economic characteristics, will be enrolled in this cross-sectional study. The final sample will therefore include a total of approximately 12,000 subjects. Sample size computation The sample size in each specific country will allow us to obtain prevalence estimates with a maximum standard error (SE) lower than ± 1.6%. Therefore, with such a sample size we will be able to provide stable prevalence estimates (with a relatively small 95% confidence interval), overall but also in each specific country.

Who may be able to join

  • individuals aged 15 years and over;
  • individuals resident of the 12 selected countries;
  • individuals able to understand and answer the questions of the questionnaire of the study in the country-specific language;
  • individuals who formally accept to participate in the study.

Who cannot join

  • No specific exclusion criteria are considered.

Trial locations and contacts

1 site in 1 country.

Italy1 site
  • DOXA Institute

    Milan, 20144

Other trials in Italy

About this study

Official title: The TackSHS Survey: a Cross-sectional Study on Secondhand Smoke in 12 European Countries

Within the TackSHS project (H2020 project grant agreement No 681040), we will conduct a European cross-sectional study, aiming at i) estimating prevalence and investigating determinants of smoking, e-cigarette use and exposure to SHS and to e-cigarette aerosol; ii) analyzing the attitudes, perceptions and behaviours of the adult European population towards policies to limit SHS exposure; iii) comparing selected smoking-related data between TackSHS and a previously conducted pan-European survey; iv) assessing mortality and morbidity from selected respiratory and cardiovascular diseases attributable to SHS exposure among adults and children in Europe; v) quantifying the economic burden associated to the exposure to SHS and e-cigarette aerosol in Europe. Overall, approximately 12,000 individuals aged 15 years or over will be enrolled in 12 different European countries (BG, DE, ES, FR, GR, IE, IT, LV, PL, PT, RO, UK). Surveys will be representative of the country-specific population in terms of sex, age, and socio-economic characteristics.

Read the detailed description

Study characteristics The TackSHS survey is a face-to-face population-based cross-sectional survey that will be conducted in 12 selected European countries, coordinated by Dr Silvano Gallus, Department of Epidemiology of the "Mario Negri" Institute (Milan, Italy).

Background Exposure to secondhand smoke (SHS) has serious adverse health effects on adults and children, causing more than 600,000 deaths each year worldwide. Estimates of prevalence of non-smokers exposed to SHS range between 20% and 60% in various European countries. The WHO recommend to develop smoke-free policies to protect non-smokers from SHS exposure. E-cigarettes have irrupted in the market over the last 5 years, and their sales and popularity have considerably grown in the European Union (EU). Approximately 7% of Europeans ever used e-cigarettes. TackSHS is a new research project funded by the European Commission (EC) within the Horizon 2020 programme (grant agreement: 681040). Within the TackSHS Project, selected work packages (WP; i.e., WP3, WP9 and WP10) involve the conduction of a survey in 12 EU countries: the TackSHS survey.

Objectives Objectives of this cross-sectional study include: i) to estimate prevalence, and investigate individual-level and country-specific determinants, of smoking, e-cigarette use, and exposure to SHS and to e-cigarette aerosol in selected European countries (WP3); ii) to analyze the attitudes, perceptions and behaviours of the adult European population towards policies to limit SHS exposure (WP3); iii) to compare selected smoking-related data collected through the TackSHS survey with those from a companion pan-European survey conducted in 2010 (WP3); iv) to assess morbidity and mortality from selected respiratory and cardiovascular diseases attributable to SHS exposure among adults and children in the European population (WP9); v) to quantify the economic burden associated to the exposure to SHS and e-cigarette aerosol in Europe (WP10).

Methods The cross-sectional survey will be conducted in 12 European countries (Bulgaria, England, France, Germany, Greece, Ireland, Italy, Latvia, Poland, Portugal, Romania, and Spain), representing geographical, legislative and cultural variations across the EU. In each of the 12 selected countries, approximately 1000 individuals, representative of the general population aged 15 years and over will be enrolled. The final sample will therefore include a total of approximately 12,000 subjects. The sample size in each specific country will allow us to obtain prevalence estimates with a maximum standard error (SE) lower than ± 1.6%. Therefore, with such a sample size we will be able to provide stable prevalence estimates (with a relatively small 95% confidence interval), overall, but also in each specific country.

Survey participants will have to satisfy the following inclusion criteria: i) 15 years and over of age; ii) residence in one of the 12 selected countries; iii) ability to understand and answer the questions of the questionnaire of the study in the country-specific language; iv) formal acceptance to participate in the study.

The multi-stage methodology will be used as the preferred sampling methodology, but other methods, including stratified or simple sampling or quota methods, will also be accepted wherever it is not possible to conduct a multistage random sampling.

Participants will be surveyed by trained interviewers through face-to-face interviews using a structured standardized questionnaire, including information on: i) socio-economic and demographic characteristics; ii) cigarette smoking habit and e-cigarette use; iii) SHS and e-cigarette aerosol exposures in different sites; iv) attitudes and perceptions on smoke-free regulations. Whenever possible, data will be collected within computer assisted personal interviews (CAPI). Alternatively, paper and pencil (P\&P) interviews will be accepted.

Once the fieldwork is completed, data will be checked for coherence and for the presence of possible errors, cleaned, and finalized into a single dataset by expert biostatisticians at the Department of Epidemiology of "Mario Negri" Institute.

According to the statistical analyses, within WP3 both univariate and multivariate (i.e., multiple logistic regression) analyses will be considered to identify sub-groups of the population or clusters of countries more frequently exposed to SHS or to passive exposure to emissions from e-cigarettes. Moreover, to evaluate the changes in time of selected smoking-related aspects, TackSHS data will be compared with data from a previous companion European survey (the PPACTE survey). Within WP9, through the use of specific algorithms, it will be possible to estimate attributable mortality and morbidity to SHS in Europe, taking advantage of: i) prevalence figures on tobacco smoking and SHS exposure from the ThackSHS survey and other selected European datasets; ii) morbidity and mortality figures from the WHO and other sources; iii) and the quantification of the association between SHS exposure and the risk of SHS-related diseases from scientific literature reviews. Within WP10, using SHS exposure figures from the TackSHS survey, a Return On Investment model will be developed to assess the cost-effectiveness, budget impact and a wider set of social return on investment metrics of selected policies aimed at reducing exposure to SHS across European countries.

Ethical Issues Although in EU countries, according to their current legislation, it is not mandatory for this type of studies (i.e., population-based cross-sectional survey) to obtain either a formal approval of the study protocol from ethics committees or the written consent signed by survey participants, following the request of the European Commission, we will satisfy these both these ethical requirements. Thus, after evaluation of the Italian Ethics Committee (i.e., the Ethics Committee of the study coordinator), the study protocol will be submitted for evaluation to the Ethics Committees of the other 11 countries where data will be collected. Moreover, formal consent (and signature in case of P\&P interview) will be obtained from each adult participant, and, in case of minors from one of their parents or legal tutors. All data will be managed anonymously, in respect of the privacy regulations in force, only for scientific purposes, without any lucrative aim. These and other measures are in agreement with national and current or forthcoming EU (i.e., Directive 95/46/EC) regulations.

Relevance, implications and dissemination Thanks to the TackSHS survey, we will provide a characterization of exposure to SHS and to e-cigarette aerosol in populations with different socioeconomic level and from various European countries. We will also provide the first estimates of morbidity and mortality due to SHS exposure at the European level, and the cost impact of interventions to control SHS exposure through purpose-built economic models. The main findings of the TackSHS survey will be disseminated on international peer-reviewed open-access journals and on the TackSHS Project website (www.tackshs.eu), and will be presented in national or international conferences.

Being tested
no intervention

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • no interventionOther

    This is an observational study. No intervention is considered

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Prevalence of Daily Exposure to Secondhand Smoke (SHS) in Indoor Settings

    Exposure to secondhand smoke (SHS) is assessed among non-smokers and indicates the general daily exposure (during a working day and during a non-working day) to SHS in indoor settings (i.e., at home, at workplace, in public and private transports and in other indoor settings). SHS exposure is self-reported and is assessed through a face-to-face interview at baseline (thus representing current exposure at interview).

    Measured: Baseline

  2. Prevalence of Exposure to Secondhand Aerosol (SHA) From Electronic Cigarettes

    Exposure to secondhand aerosol (SHA) is assessed among electronic cigarette non-users and indicates the general daily exposure (during a working day and during a non-working day) to SHA in indoor settings (i.e., at home, at workplace, in public and private transports and in other indoor settings). SHA exposure is self-reported and is assessed through a face-to-face interview at baseline (thus representing current exposure at interview).

    Measured: Baseline

Secondary outcomes (2)
  1. Prevalence of Never, Current and Former Smokers

    Cigarette consumption is assessed at baseline (thus representing current use at interview) through self-reported questions on lifetime use. Never smokers were defined as participants who had never smoked or had smoked less than 100 cigarettes in their lifetime. Smokers were defined as participants who reported smoking at least 100 cigarettes (including hand-rolled cigarettes) during their lifetime. Current smokers were smokers who reported smoking at the time they participated in this survey, while former smokers were smokers who stopped smoking by the time they participated in this survey.

    Measured: Baseline

  2. Prevalence of Never, Current and Former Electronic Cigarette Users

    Electronic cigarette use is assessed at baseline (thus representing current use at interview) through self-reported questions on lifetime use. Current electronic cigarette users were defined as those who reported using the electronic cigarette occasionally (5 days or less) or regularly (more than 5 days) in the last 30 days. Former users of electronic cigarette were those who reported using it in the part but not over the last 30 days.

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted10 Oct 2016 (estimated)
  2. Study startDec 2016
  3. Primary completionOct 2018
  4. Study completionOct 2018

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Other
Time perspective
Cross-sectional
Enrolment
11,902 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02928536
Sponsor's protocol ID
6895
Status last verified
Oct 2019
First submitted
4 Oct 2016
Last updated
20 Nov 2019
Data monitoring committee
No
Individual data sharing
No: No plan is made to share IPD. Main results (aggregated data) will be published in peer-reviewed open-access journals

Publications

  • Fernandez E, Lopez MJ, Gallus S, Semple S, Clancy L, Behrakis P, Ruprecht A, Gorini G, Lopez-Nicolas A, Radu-Loghin C, Soriano JB; TackSHS Project Investigators; TackSHS Project Investigators. Tackling second-hand exposure to tobacco smoke and aerosols of electronic cigarettes: the TackSHS project protocol. Gac Sanit. 2020 Jan-Feb;34(1):77-82. doi: 10.1016/j.gaceta.2019.07.002. Epub 2019 Sep 23.

    PubMed 31558386
  • Amalia B, Liu X, Lugo A, Fu M, Odone A, van den Brandt PA, Semple S, Clancy L, Soriano JB, Fernandez E, Gallus S; TackSHS Project Investigators. Exposure to secondhand aerosol of electronic cigarettes in indoor settings in 12 European countries: data from the TackSHS survey. Tob Control. 2021 Jan;30(1):49-56. doi: 10.1136/tobaccocontrol-2019-055376. Epub 2020 Mar 2.

    PubMed 32123139

Questions about this trial

What is this clinical trial studying?

An observational study of Second Hand Tobacco Smoke, run by Mario Negri Institute for Pharmacological Research at 1 site in Italy.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 20 Nov 2019. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in Italy. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Yes. Results are posted in the registry (first posted 20 Nov 2019). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Prevalence of Daily Exposure to Secondhand Smoke (SHS) in Indoor Settings (time frame: Baseline). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02928536, which also lists 2 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 20 Nov 2019.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in